דוגמנות שבץ בעכברים - העורקים התיכון ספיגה מוחין עם דגם נימה

Executive Industry Relevance

The filament-based middle cerebral artery occlusion (MCAO) model enables reproducible induction of focal cerebral ischemia in mice, supporting preclinical evaluation of neuroprotective and thrombolytic candidates. By allowing controlled transient or permanent ischemia, the model facilitates mechanistic de-risking of stroke therapeutics prior to clinical translation. Its non-invasive nature and behavioral readouts enhance translational continuity and predictive confidence in early discovery pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in ischemic pathways through reproducible cortical and striatal lesion induction.
• Operational Value: Supports functional target validation by linking molecular targets to observable neurological deficits and infarct volume.
• Predictive Value: Facilitates portfolio triage by modeling dose- and time-dependent ischemic injury severity.

Screening & Assay Development

• Assay Readiness: Provides a standardized, surgically controlled platform for compound screening with quantifiable behavioral and histological endpoints.
• Reproducibility: Silicon-coated filament technique ensures consistent MCA territory occlusion, reducing inter-animal variability in infarct size.
• Scalability: Minimally invasive approach allows for cohort expansion without craniectomy-related morbidity, supporting medium-throughput efficacy testing.

Translational & Preclinical Research

• Disease Relevance: Models proximal MCA occlusion, which mirrors the most common site of arterial thromboembolism in human ischemic stroke.
• Translational Continuity: Reperfusion via filament removal recapitulates spontaneous or tPA-mediated clot lysis, enabling evaluation of recanalization therapies.
• Risk-Adjusted Advancement: Lesion severity gradients (30 vs 60 min ischemia) allow stratification of therapeutic efficacy across mild to severe injury models.

Pipeline & Workflow Integration

The MCAO filament model integrates into the stroke discovery continuum from target validation through lead optimization to preclinical efficacy testing, enabling go/no-go decisions based on neurological and histopathological outcomes.

• Discovery Biology: Supports pathway clarification by isolating the effect of MCA territory ischemia on motor and behavioral phenotypes.
• Screening: Enables quantitative assessment of neuroprotection via neurological deficit scores and infarct volume reduction.
• Analytics: Generates measurable dependent variables including behavioral circling, limb flexor posture, and histological necrosis for comparative condition analysis.
• Translational Research: Connects early efficacy findings to preclinical validation through reperfusion modeling and delayed treatment paradigms.
• Enterprise Reuse: Establishes a reusable surgical platform for iterative testing of multiple candidates across ischemic durations.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by providing a controlled, reproducible model of focal ischemia with defined anatomical specificity.
• Operational Value: Standardized filament preparation and insertion protocol enhance inter-laboratory consistency and reduce procedural failure rates.
• Strategic Value: Enables earlier go/no-go decisions by quantifying infarct progression and functional recovery, reducing late-stage biological risk.
• Portfolio Impact: Supports risk-adjusted prioritization of stroke candidates based on efficacy across transient and permanent ischemia paradigms.

Implementation Considerations

• Requires microsurgical expertise in vascular dissection and filament handling to avoid vessel trauma or incomplete occlusion.
• Dependence on precision instrumentation including microsutures, clips, and heating platforms to maintain physiological conditions.
• Necessitates cross-team standardization of anesthesia, temperature monitoring, and postoperative care to minimize welfare-related variability.
• Adaptation considerations include filament length and coating consistency across mouse strains and ages to ensure reproducible MCA territory targeting.
• Practical limitations include operator-dependent variability in filament placement and the need for sham controls to isolate surgical effects from ischemic injury.

Biopharma FAQs